We are conducting a phase 1/2, open-label, multicenter trial aimed at optimizing cell engraftment (ClinicalTrials.gov identifier: NCT03163511).
Researchers conducting a phase I/II, open-label, multicenter trial aimed at optimizing cell engraftment with device-encapsulated pancreatic precursor cells, and reported interim, one-year outcomes in one study group that received twothreefold higher cell doses in devices...
A multicenter trial of the CAR T-cell product MB-106 has treated its first patient, Mustang Bio, Inc announced.
Such details provide a deeper understanding and appreciation for Multicenter Trial Aimed At Optimizing Cell.
The study, which involved 22 institutions and tested a product called KTE-C19 (anti-CD19 CAR), is the first multicenter trial of this cellular immunotherapy-based treatment approach for lymphoma.
In the phase 1/2, open-label, multicenter trial aimed at optimizing cell engraftment (ClinicalTrials.gov identifier: NCT03163511), the VC-02 combination product was implanted in T1D patients with undetectable endogenous insulin production...
Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.
We are conducting a phase 1/2, open-label, multicenter trial aimed at optimizing cell engraftment (ClinicalTrials.gov identifier: NCT03163511). Here we report interim, 1-year outcomes in one study group that received 23-fold higher cell doses in devices with an optimized membrane...
Investigators affiliated with the Children's Oncology Group (COG) have launched a multicenter trial aimed at determining why the relapse and survival rates of children with acute lymphoblastic leukemia (ALL) differ among the major racial and ethnic groups living in the United States.
